2022

1. Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity

   Biomedicines, Vol. 10, Núm. 3

2. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

   Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

3. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

   Journal of Clinical Medicine, Vol. 11, Núm. 2

4. Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study

   Gastroenterologia y Hepatologia, Vol. 45, Núm. 3, pp. 165-176

5. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

   Journal of Clinical Medicine, Vol. 11, Núm. 24